Can Flashing Lights and Sound Unhurried Alzheimer’s Disease?
A novel approach to Alzheimer’s treatment involving flickering lights and sound is showing promise in clinical trials. Researchers are investigating whether this non-invasive sensory stimulation can slow cognitive decline and offer a new avenue for combating the devastating disease.
A Different Approach to Alzheimer’s Treatment
While pharmaceutical companies invest heavily in drug therapies for Alzheimer’s disease, a team led by Dr. Annabelle Singer, an associate professor and biomedical engineer at Georgia Institute of Technology and Emory University, is pursuing a different path. Singer’s research focuses on understanding how neural activity breaks down in Alzheimer’s patients and using that knowledge to develop brain stimulation techniques to improve brain health [1].
How Does It Work?
The treatment involves a device resembling ski goggles and headphones. The goggles deliver flickering lights at approximately 40 Hz – five times faster than a typical strobe light – while the headphones emit a quick-clicking, beeping sound. This combination aims to decode memory in Alzheimer’s patients by exploring how failures in neural activity lead to memory impairment [1]. Previous research has indicated that this 40Hz stimulation can mobilize microglia to remove amyloid beta, a protein associated with neurotoxic events in Alzheimer’s disease [3].
Clinical Trial Underway
A Phase 3 clinical trial, involving nearly 700 patients across 70 sites in the United States, is currently underway, led by Cognito Therapeutics [1]. Dr. Singer serves as a scientific advisor to the company. The goal is to determine if this stimulation can slow or halt cognitive decline compared to a control group [1]. Results are anticipated by the complete of 2026.
The Scope of the Problem
More than 7 million Americans over the age of 65 are living with Alzheimer’s disease, and that number is projected to reach 13.8 million by 2060 without significant medical advancements. Globally, approximately 57 million people suffer from dementia, with Alzheimer’s being the most common form [1].
Current Treatments and Their Limitations
While the FDA has recently approved new drugs like lecanemab and donanemab, their effectiveness is moderate, reducing decline by roughly 27% and 35% respectively. These treatments also carry risks, including potentially fatal cerebral edema or hemorrhage, and come with a high annual cost of approximately $30,000, limiting accessibility [1].
Accessibility and Future Potential
Dr. Singer believes that this non-invasive stimulation method could be a more accessible and affordable solution. “One thing that excites us is how accessible this intervention could be,” she says. “If we have a safe, low-risk method, that completely changes the equation.” [1]. The most common side effect observed in testing has been headache, and the stimulation has not triggered seizures even in individuals with seizure disorders [1].
Dr. Singer’s Background
Dr. Annabelle Singer’s interest in the intersection of light, sound, and the brain dates back to her youth, initially sparked by her fascination with stage design. She is currently the McCamish Foundation Early Career Professor in the Coulter Department of Biomedical Engineering at Georgia Tech and Emory University [2]. Her research focuses on understanding how neural activity produces memories and regulates brain immune function [2].